Recent advances focus on reducing toxicity while maintaining efficacy. Reduced-intensity conditioning regimens are being developed to lower the toxic burden, particularly in older or frail patients. Targeted therapies and immunotherapies are also being explored to replace or supplement traditional chemotherapeutic agents, offering potentially less toxic alternatives.
